GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Dr. Greg Riely offers his view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?

Direct download: GRACEcastUC-069_Lung-Video_Riely_on_EGFR_Mutation_After_Chemo.m4v
Category:Lung-Cancer-Video -- posted at: 12:00am PST

Dr. Oxnard from Dana Farber Cancer Institute provides his insight on which patients with advanced non-small cell lung cancer he pursues molecular testing for, and which molecular markers are the highest priority.

Direct download: GRACEcastUC-068_Lung-Video_Oxnard_on_Molecular_Marker_Testing.m4v
Category:Lung-Cancer-Video -- posted at: 11:59pm PST

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.

Direct download: GRACEcast-145_Lung-Video_Leighl_Highlights_Squam_and_antiPD1.m4v
Category:Lung-Cancer-Video -- posted at: 6:32pm PST

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.

Direct download: GRACEcast-145_Lung-Audio_Leighl_Highlights_Squam_and_antiPD1.mp3
Category:Lung-Cancer-Audio -- posted at: 6:31pm PST

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.

Direct download: GRACEcast-144_Lung-Video_Leighl_Highlights_MEK_KRAS_Mutation.m4v
Category:Lung-Cancer-Video -- posted at: 4:46pm PST

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.

Direct download: GRACEcast-144_Lung-Audio_Leighl_Highlights_MEK_KRAS_Mutation.mp3
Category:Lung-Cancer-Audio -- posted at: 4:46pm PST

Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, reviews the general concept of cancer staging, the basic workup and staging of pancreatic cancer, and the implications of this process on treatment recommendations.


Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, reviews the general concept of cancer staging, the basic workup and staging of pancreatic cancer, and the implications of this process on treatment recommendations.


Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, provides a general introduction to the form and function of the pancreas, along with a description of the magnitude of the impact of pancreatic cancer in the US.


Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, provides a general introduction to the form and function of the pancreas, along with a description of the magnitude of the impact of pancreatic cancer in the US.


Dr. Sarah Goldberg addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.

Direct download: GRACEcastUC-067_Lung-Video_Goldberg_on_Targeted_Rx_Adjuvant.m4v
Category:Lung-Cancer-Video -- posted at: 6:11pm PST

Dr. Lecia Sequist of Massachusetts General Hospital describes the new targets she envisions as relevant for effective treatments in lung cancer over the next several years. 

Direct download: GRACEcastUC-066_Lung-Video_Sequist_on_Emerging_Targets_in_LC.m4v
Category:Lung-Cancer-Video -- posted at: 6:10pm PST

Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

Direct download: GRACEcastUC-065_Lung-Video_Wakelee_on_Targeted_Rx_for_LC.m4v
Category:Lung-Cancer-Video -- posted at: 11:51am PST

Drs. Ross Camidge and Corey Langer offer their insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent for lung cancer.

Direct download: GRACEcastUC-064_Lung-Video_Camidge_and_Langer_on_AR.m4v
Category:Lung-Cancer-Video -- posted at: 11:47pm PST

Dr. Sumanta (Monty) Pal reviews the questions on the role of surgery and what type of surgery to pursue for early stage kidney cancer.

Direct download: GRACEcastUC-063_Kidney-Video_Pal_on_Surgery_for_RCC.m4v
Category:Kidney-Cancer-Video -- posted at: 11:46pm PST

Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN, discusses the evidence and his personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

Direct download: GRACEcastUC-062_Lung-Video_Spigel_on_Maintenance_Therapy.m4v
Category:Lung-Cancer-Video -- posted at: 11:42pm PST

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.

Direct download: GRACEcast-141_Lung-Video_Leighl_Highlights_in_LC_2012_Part_2.m4v
Category:Lung-Cancer-Video -- posted at: 8:04pm PST

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.

Direct download: GRACEcast-141_Lung-Audio_Leighl_Highlights_in_LC_2012_Part_2.mp3
Category:Lung-Cancer-Audio -- posted at: 8:04pm PST

Dr. Alan Sandler from OHSU describes how acquired resistance to targeted therapies in lung cancer is similar to what is seen with chemo and comments on how he manages patients demonstrating gradual acquired resistance in advanced lung cancer.


Dr. Greg Riely, Memorial Sloan-Kettering, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.


Dr. Ravi Salgia from University of Chicago provides his general strategy for patients with advanced non-small cell lung cancer who are candidates for maintenance therapy after first line treatment.

Direct download: GRACEcastUC-059_Lung-Video_Salgia_on_Maintenance_Therapy.m4v
Category:Lung-Cancer-Video -- posted at: 2:18am PST

Dr. William Pao explains the caveats of molecular testing in terms of differences in testing methods through different laboratories and the heterogeneity of molecular findings in different biopsies even within the same individual with lung cancer.


Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, explains the range of options and his approach to first line treatment of metastatic kidney cancer.

Direct download: GRACEcastUC-056_Kidney-Video_Pal_on_1st_Line_RCC_Options.m4v
Category:Kidney-Cancer-Video -- posted at: 6:23pm PST

Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, discusses leading challenges he sees for effective delivery of the best cancer care over the next decade.


Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.

Direct download: GRACEcast-140_Lung-Video_Leighl_Highlights_in_LC_2012_Part_1.m4v
Category:Lung-Cancer-Video -- posted at: 4:59pm PST

Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.

Direct download: GRACEcast-140_Lung-Audio_Leighl_Highlights_in_LC_2012_Part_1.mp3
Category:Lung-Cancer-Audio -- posted at: 4:58pm PST

Dr. Geoffrey Oxnard conveys a central theme that the benefits of molecular oncology and optimal application of targeted therapies are dependent on a change in collecting tissue that works to obtain far more tissue than was historically required.

Direct download: GRACEcastUC-055_Lung-Video_Oxnard_on_Importance_of_Tissue.m4v
Category:Lung-Cancer-Video -- posted at: 1:03pm PST

Dr. Heather Wakelee from Stanford University expresses her practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.


Dr. Karen Reckamp, City of Hope Cancer Center, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.


Dr. Rosalyn Juergens, McMaster University, explains her approach to management of acquired resistance to targeted therapies in patients with a "driver mutation" and respond well initially to treatment.


Dr. David Harpole of Duke University reviews advances in lung cancer surgery, covering techniques ranging from video-assisted thoracic surgery to robotic surgery to sub-lobar resections and other developments offering new promising alternatives.

Direct download: GRACEcast-139_Lung-Video_Advances_in_LC_Surgical_Techniques.m4v
Category:Lung-Cancer-Video -- posted at: 3:30pm PST

Dr. David Harpole of Duke University reviews advances in lung cancer surgery, covering techniques ranging from video-assisted thoracic surgery to robotic surgery to sub-lobar resections and other developments offering new promising alternatives.

Direct download: GRACEcast-139_Lung-Audio_Advances_in_LC_Surgical_Techniques.mp3
Category:Lung-Cancer-Audio -- posted at: 3:29pm PST

Dr. Alan Sandler, Oregon Health and Science University, considers the various options for maintenance therapy as well as a potential treatment break after first line treatment of advanced non-small cell lung cancer.

Direct download: GRACEcastUC-051_Lung-Video_Sandler_on_Options_for_Maint_Rx.m4v
Category:Lung-Cancer-Video -- posted at: 6:03pm PST

Dr. Sumanta (Monty) Pal of City of Hope Cancer Center discusses the current role of interleukin-2 (IL-2) in the context of many other treatment alternatives for metastatic renal cell carcinoma.

Direct download: GRACEcastUC-050_Kidney-Video_Pal_on_Role_of_IL-2_for_RCC.m4v
Category:Kidney-Cancer-Video -- posted at: 6:02pm PST

Dr. Karen Kelly of University of California, Davis, presents her current view on using molecular markers in early stage non-small cell lung cancer and explains the RADIANT study that she leads.


Dr. Bob Doebele from the University of Colorado reviews which molecular markers have the strongest evidence to support routine testing, and which patients with advanced non-small cell lung cancer he favors molecular testing for. 


Dr. Sumanta (Monty) Pal, City of Hope Cancer Center, summarizes basic stages of bladder cancer, value of surgery, and survival benefit of neoadjuvant (pre-operative) chemotherapy for higher risk muscle-invasive bladder cancer. 


Dr. Sarah Goldberg notes that while maintenance therapy after first line treatment of advanced NSCLC is always worthy of a discussion, many patients need and benefit from a break from treatment to recover before pursuing additional therapy.

Direct download: GRACEcastUC-047_Lung-Video_Goldberg_Maint_Rx_vs_Rx_Break.m4v
Category:Lung-Cancer-Video -- posted at: 11:08pm PST

Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.

Direct download: GRACEcastUC-046_Lung-Video_Camidge_Langer_Future_Molec_Rx.m4v
Category:Lung-Cancer-Video -- posted at: 11:07pm PST

Dr. David Spigel, Sarah Cannon Cancer Center, reviews which patients with lung cancer he feels should undergo molecular testing, as well as describing the potential value of immediate, reflex testing for molecular targets.


Dr. Larry Einhorn, Indiana University, expresses his concerns about the cost of developing cancer drugs and the challenge of paying for extremely expensive cancer treatments that are given in anticipation of modest clinical benefits.

Direct download: GRACEcastUC-043_CA-101-Video_Einhorn_Managing_Cancer_Rx_Costs.m4v
Category:Cancer-101-Video -- posted at: 11:45pm PST

Dr. Larry Einhorn, Indiana University, explains why some cancers such as testicular cancer can have such a high cure rate while most others are far more challenging to cure with our current systemic therapies, offering an optimistic view of the future.


Dr. Sumanta (Monty) Pal of City of Hope Cancer Center in Duarte, CA describes optimal management of kidney cancer that is confined to the kidney, including surgery and the role of any additional post-surgical treatment. 

Direct download: GRACEcastUC-041_Kidney-Video_Pal_on_Early_RCC_Management.m4v
Category:Kidney-Cancer-Video -- posted at: 11:43pm PST

Dr. Lecia Sequist provides her thoughts on how molecular oncology can soon begin affecting treatment plans for a broader range of patients with lung cancer, including those with squamous NSCLC and other lung cancer histologies.


Dr. Greg Riely from Memorial Sloan-Kettering notes how he feels molecular marker results for patients with earlier stage lung cancer can potentially be valuable.


Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing patients with advanced NSCLC who experience acquired resistance, the progression of cancer after a good initial response to a targeted therapy.

Direct download: GRACEcastUC-038_Lung-Video_Oxnard_on_AR_to_Targeted_Therapy.m4v
Category:Lung-Cancer-Video -- posted at: 6:12pm PST

Dr. Karen Reckamp, City of Hope Cancer Center, reviews her thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.

Direct download: GRACEcastUC-037_Lung-Video_Reckamp_on_Repeat_Biopsy_Timing.m4v
Category:Lung-Cancer-Video -- posted at: 12:57am PST

Dr. William Pao describes how the developers of MyCancerGenome.org envision the website resource being used to help cancer patients, both now and in the future.

Direct download: GRACEcastUC-036_Lung-Video_Pao_on_Goals_for_Developing_MCG.m4v
Category:Lung-Cancer-Video -- posted at: 2:15pm PST

Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therapies for patients with lung cancer.

Direct download: GRACEcastUC-035_Lung-Video_Juergens_Promising_Novel_Rx.m4v
Category:Lung-Cancer-Video -- posted at: 1:25pm PST

Dr. Ravi Salgia from University of Chicago explains his approach to management of acquired resistance to a targeted therapy for advanced NSCLC, both in the setting of a single area of progression and also when disease progression is more diffuse.

Direct download: GRACEcastUC-034_Lung-Video_Salgia_on_Acquired_Resistance.m4v
Category:Lung-Cancer-Video -- posted at: 5:59pm PST